AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline

Aardvark Therapeutics faces an October 13, 2026 deadline related to a securities-fraud class action lawsuit, according to Bernstein Liebhard LLP. The notice provides no allegations, claimed damages, or operational impact, but the pending litigation represents a reputational and legal risk for the company.

Analysis

This is not an operating catalyst; it is a claimant-deadline advertisement with no independent assessment of merits, damages, insurance coverage, or the underlying disclosure record. For AARD, the relevant market variable is whether litigation prompts a restatement, revised regulatory timeline, financing constraint, or management distraction—not the October 13 procedural date itself. Absent a new complaint filing, lead-plaintiff appointment, or company response containing incremental allegations, the near-term price impact should be limited and any headline-driven weakness may be liquidity-amplified rather than fundamentally informative.

The more consequential second-order risk is capital-market access. Pre-commercial biotech valuation depends disproportionately on runway and probability-adjusted pipeline value; a sustained litigation overhang can widen the discount needed for an ATM, follow-on, or partnership financing over the next 3-12 months. Monitor cash runway versus quarterly burn, upcoming clinical/regulatory milestones, insider transactions, and any change in D&O insurance disclosures. A material guidance cut, trial delay, FDA correspondence, or financing below market would validate a bearish thesis; dismissal of the complaint or no operational deterioration through the next earnings update would weaken it.

Contrarianly, class-action reminders often attract attention after the underlying drawdown rather than create new information. If AARD has sufficient cash through its next value-inflecting data event and the complaint merely repackages previously disclosed risks, incremental downside from this notice alone is likely low. Given the absence of allegation-specific evidence and limited liquidity, avoid treating this as a stand-alone short catalyst.

Key Decisions for Investors

• No new directional position solely on this notice; classify AARD as an event-risk watch item through the October 13 deadline and next earnings release.
• For existing AARD longs, reduce gross exposure or hedge into the next company filing if cash runway is under 12 months or if an equity raise appears likely; litigation plus financing risk can compound dilution-driven downside over 3-12 months.
• Consider a tactical short only after independently confirming a new operational catalyst—trial/regulatory delay, guidance revision, or discounted financing—not on the procedural deadline. Cover if the company reaffirms milestones and demonstrates runway beyond the next major data readout.
• Set alerts for lead-plaintiff appointment, any motion-to-dismiss outcome, SEC filings referencing litigation reserves/insurance, and financing disclosures; these are more likely than the deadline itself to change fundamental valuation.